Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

HALO vs SYRE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

HALO Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 8–2 Matrix Metrics)

HALO Overall Winner 6-Pillar Tally: HALO 6 – 0 SYRE Matrix Metrics: HALO 8 – 2 SYRE

As of Nov 16, 2026, Halozyme Therapeutics, Inc. (HALO) is the stronger overall head-to-head candidate over Spyre Therapeutics, Inc. (SYRE) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HALO carries a Unified Composite Score of 59.9/100 (HOLD) at $97.43 (9.5x Forward P/E, 56.7% operating margin), whereas SYRE carries 44.4/100 (HOLD) at $99.97 (N/M Forward P/E, 0.0% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About HALO vs SYRE
HALO NASDAQ Head-to-Head Winner
Halozyme Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$97.43
-2.83% 1D
Market Cap $11.5B
TTM Revenue $1.80B
Forward P/E 9.5x
Beta / 30D Vol 0.57β · 59% Vol
Unified Composite Score
59.9 / 100 HOLD
Tech 45.0 Fund 56.0 Flow 70.0 Mom 55.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 24
RSI-14: 24.3 · SMA20: $118.42 · SMA50: $114.31
SYRE NASDAQ
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.97
-3.88% 1D
Market Cap $9.8B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.75β · 59% Vol
Unified Composite Score
44.4 / 100 HOLD
Tech 31.0 Fund 33.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 53.5 · SMA20: $98.78 · SMA50: $91.70

6-Pillar Scorecard Institutional Category Breakdown (HALO 6 – 0 SYRE)

Columns: Metric · HALO · SYRE
1. Valuation Multiples HALO
Forward P/E 9.5x N/M
Trailing P/E 25.2x N/M
PEG Ratio N/M N/M
EV / Revenue 7.6x N/M
2. Growth & Scale HALO
Revenue Growth (YoY) +39.2% +0.0%
Earnings Growth (YoY) +40.6% -99.7%
TTM Revenue (USD) $1.80B N/A
Market Cap $11.5B $9.8B
3. Profitability & Quality HALO
Gross Margin 76.0% N/A
Operating Margin 56.7% 0.0%
Net Profit Margin 26.9% 0.0%
Return on Equity (ROE) 216.4% -35.0%
4. Balance Sheet & Cash Flow HALO
Cash Generation (TTM) $598M N/A
Cash Flow Margin 33.2% N/A
Net Cash / Leverage $2.22B Net Debt $10.06 Book/Sh · -35.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning HALO
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 39.7% (26th %ile) 87.9% (10th %ile)
Put/Call OI Skew 0.36x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat HALO
OpEx & R&D Intensity 19.3% of Rev ($348M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: HALO (8) vs SYRE (2)
Institutional Metric HALO SYRE Criterion Row Edge
Market Capitalization
Scale
$11.5B $9.8B Larger Scale HALO
Trailing P/E Ratio
Valuation
25.2x N/M Lower Multiple HALO
Forward P/E Ratio
Valuation
9.5x N/M Lower Multiple HALO
Revenue Growth (YoY)
Growth
+39.2% +0.0% Higher Growth HALO
Operating Margin (TTM)
Profitability
56.7% 0.0% Higher Margin HALO
Net Profit Margin
Profitability
26.9% 0.0% Higher Margin HALO
Return on Equity (ROE)
Capital Efficiency
216.4% -35.0% Higher ROE HALO
52-Week Range Position
Momentum
50% ($61–$134) 88% ($22–$111) Stronger Trend SYRE
Beta / 30D Volatility
Risk Regime
0.57β · 59% Vol 1.75β · 59% Vol Lower Realized Risk SYRE
Unified Institutional Score
Composite Signal
59.9 / 100 (HOLD) 44.4 / 100 (HOLD) Higher Composite HALO
Trailing 12M Revenue (USD)
Operating Scale
$1.80B N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
76.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 7.6x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$598M ($2.22B Net Debt) N/A ($10.06 Book/Sh · -35.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SYRE +45.14 pp
HALO: -20.03% · SYRE: +25.11%
3M Horizon HALO +0.18 pp
HALO: -7.11% · SYRE: -7.29%
6M Horizon HALO +1.83 pp
HALO: +44.47% · SYRE: +42.64%
1Y Horizon SYRE +304.88 pp
HALO: +36.86% · SYRE: +341.74%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on HALO vs SYRE. Trailing 12-month operating profitability (HALO 56.7% vs SYRE 0.0%) and valuation multiples (HALO 9.5x vs SYRE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

HALO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.80B
Gross Margin76.0%
Op. Margin56.7%
ROE / Fwd P/E216.4% · 9.5x
SYRE ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-35.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
HALO CONSOLIDATION
58d in phase · OBV DISTRIBUTION
Current IV 39.7%
IV Percentile 26th %ile
Put/Call OI Skew 0.36x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact HALO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SYRE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 87.9%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SYRE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
HALO Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $11.5B market capitalization and 56.7% operating margin.
OpEx & R&D Reinvestment 19.3% of Rev ($348M)
90D Engineering Disclosures 0 Published
SYRE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $9.8B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ HALO vs SYRE Key Questions & Quantitative Answers

As of Nov 16, 2026, Halozyme Therapeutics, Inc. (HALO) is the stronger overall head-to-head candidate over Spyre Therapeutics, Inc. (SYRE) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HALO carries a Unified Composite Score of 59.9/100 (HOLD) at $97.43 (9.5x Forward P/E, 56.7% operating margin), whereas SYRE carries 44.4/100 (HOLD) at $99.97 (N/M Forward P/E, 0.0% operating margin). Technically, HALO sits in a Neutral phase (RSI 24.3, CONSOLIDATION options structure) and SYRE sits in a Neutral phase (RSI 53.5, UNCLASSIFIED options structure).

HALO leads the Growth & Scale pillar: HALO posts +39.2% YoY revenue growth and +40.6% YoY earnings growth on $1.80B TTM revenue (76.0% gross margin, 56.7% operating margin), compared with SYRE at +0.0% YoY revenue growth and -99.7% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, HALO generates $1.80B in USD-normalized revenue versus N/A for SYRE. In operating R&D and SG&A reinvestment, HALO deploys 19.3% of Rev ($348M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SYRE.

HALO screens cheaper on headline valuation multiples. HALO trades at 9.5x Forward P/E, 25.2x Trailing P/E, N/M PEG, and 7.6x EV/Revenue (33.2% FCF margin), whereas SYRE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HALO (216.4% ROE) versus SYRE (-35.0% ROE) capital efficiency.

In options market volatility and institutional positioning, HALO carries 39.7% implied volatility (26th %ile, Balanced (25th–60th %ile)), a 0.36x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.57β · 59% Vol realized risk). By comparison, SYRE carries 87.9% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.75β · 59% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.